This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Johnson & Johnson Gets European Approval for Ebola Vaccine
by Zacks Equity Research
J&J (JNJ) gets approval from the European Commission for Ebola vaccine.
AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Powerful Proof Anyone Can Invest for an Early Retirement - July 02, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Ranked Income Stocks to Buy for July 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, July 2nd.
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
by Benjamin Rains
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
What Makes AbbVie (ABBV) a New Strong Buy Stock
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
by Zacks Equity Research
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
by Benjamin Rains
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
Signs That Your Trading Will Ruin Your Retirement - June 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
5 Great Dividend Growth Stocks Amid Market Volatility
by Sweta Killa
The second wave of coronavirus infections has flared up volatility and made investors scurry for safety and regular income. This has resulted in higher appeal for dividend investing.
Novartis Gets Positive CHMP View for Cosentyx Label Expansion
by Zacks Equity Research
Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.
3 Top Dividend Stocks to Maximize Your Retirement Income - June 29, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Wall Street Braces for Higher Bouts of Volatility: 5 Safe Picks
by Tirthankar Chakraborty
As markets remain disturbed, investing in stocks that provide excellent risk-adjusted returns seems judicious. The best way to go about doing this is by creating a portfolio of low-beta stocks.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Timing the Market, Is it Possible? - June 26, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
by Zacks Equity Research
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
by Zacks Equity Research
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Can the S&P500 Break 3,200 this Summer?
by John Blank
What could the catalysts be?
Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
Simple Secrets Anyone Can Use to Reach Early Retirement - June 24, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
3 Stocks to Buy on New Drug Approvals by FDA
by Manaswita Ghosh Dutta
In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH